CN104013595B - 一种盐酸司来吉兰制剂及其制备工艺 - Google Patents

一种盐酸司来吉兰制剂及其制备工艺 Download PDF

Info

Publication number
CN104013595B
CN104013595B CN201310065036.3A CN201310065036A CN104013595B CN 104013595 B CN104013595 B CN 104013595B CN 201310065036 A CN201310065036 A CN 201310065036A CN 104013595 B CN104013595 B CN 104013595B
Authority
CN
China
Prior art keywords
selegilinehydrochloride
preparation
prepared
capsule
extrusion spheronization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201310065036.3A
Other languages
English (en)
Other versions
CN104013595A (zh
Inventor
沈蔡月
朱礼根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ANHUI BIOCHEM BIO-PHARMACEUTICAL Co Ltd
Original Assignee
ANHUI BIOCHEM BIO-PHARMACEUTICAL Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ANHUI BIOCHEM BIO-PHARMACEUTICAL Co Ltd filed Critical ANHUI BIOCHEM BIO-PHARMACEUTICAL Co Ltd
Priority to CN201310065036.3A priority Critical patent/CN104013595B/zh
Publication of CN104013595A publication Critical patent/CN104013595A/zh
Application granted granted Critical
Publication of CN104013595B publication Critical patent/CN104013595B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明涉及一种盐酸司来吉兰制剂及其制备工艺,本发明将盐酸司来吉兰溶入溶剂中,再通过挤出滚圆法制备微丸,最后灌装胶囊。本发明公开的制剂及其工艺,较好的解决了盐酸司来吉兰在制剂中的含量均匀度不易合格及灌装胶囊过程中易出现装量差异过大问题。本发明的制备方法工艺简单可行,产品质量稳定可控。

Description

一种盐酸司来吉兰制剂及其制备工艺
技术领域
本方面涉及一种以盐酸司来吉兰为活性成份的口服制剂,属于医药技术领域。
背景技术
盐酸司来吉兰(Selegiline Hydrochloride),其化学名称为:(R)-N-a-二甲基-N-(2-丙炔基)苯乙胺盐酸盐。
其化学结构式如下:
帕金森氏病是常见的中枢神经系统退行性病变,多发于中老年人,65岁以上人群中患病率大约为1%,晚期帕金森氏病长期试用左旋多巴类制剂,常出现疗效减退和长期多巴治疗综合症,包括运动不良,症状波动,剂末现象,开关现象等。盐酸司来吉兰为选择性β型单胺氧化酶抑制剂,他能够选择性不可逆地抑制多巴胺降解为高香草酸,从而增加了多巴胺的蓄积;同时也能减少突触前膜对多巴胺的再摄取,促进了多巴胺的释放,这些都延长了外源性及内源性多巴胺的作用时间,是帕金森病患者临床症状得到改善。
在制剂的制备过程中,如果药物规格含量较小,一般存在药物混合不均匀问题,这样容易造成药品含量均匀度不合格,另外胶囊剂生产过程中由于颗粒流动性不好,容易出现填充重量差异过大的问题。
发明内容
为了解决制剂过程中由于盐酸司来吉兰含量很小易产生与辅料混合不均匀问题和胶囊剂生产过程中由于颗粒流动性不好,容易出现填充重量差异过大的问题。本发明提供一种质量可控盐酸司来吉兰胶囊剂的制备方法。
实现上述目的技术解决方案如下:
一种盐酸司来吉兰制剂,其特征在于按下列重量份的原料组成:
盐酸司来吉兰 5份、微晶纤维素60~100份、羟丙纤维素10~30份,纯化水5~20份。
上述盐酸司来吉兰制剂的制备方法包括下列工艺步骤:
(1)称取上述微晶纤维素、羟丙基纤维素分别过60~120目筛网;
(2)将微晶纤维素与羟丙基纤维素混合均匀,得混合物料;
(3)称取上述盐酸司来吉兰和纯化水,然后将盐酸司来吉兰完全溶于纯化水中,得润湿剂;
(4)将润湿剂加入到混合物料中制备软材;
(5)通过挤出滚圆法制备微丸;
(6)以常规的方法制备胶囊。
本发明的有益技术效果是:将盐酸司来吉兰溶于纯化水中作为润湿剂,能使盐酸司来吉兰与其它辅料易于混合。通过挤出滚圆法制备盐酸司来吉兰微丸,微丸在填入胶囊剂的过程中流动好,装量差异变化小。本发明工艺较简单,特别是产品质量能够很好控制。
具体实施方式
下面结合实施例,对本发明做进一步地的描述。
实施例1
取下列原料:盐酸司来吉兰 5g、微晶纤维素60g、羟丙纤维素30g,纯化水10g。
盐酸司来吉兰胶囊剂的制备方法包括下列工艺步骤:
(1)称取上述微晶纤维素、羟丙基纤维素分别过60~120目筛网;
(2)将微晶纤维素与羟丙基纤维素混合均匀,得混合物料;
(3)称取上述盐酸司来吉兰和纯化水,然后将盐酸司来吉兰完全溶于纯化水中,得润湿剂;
(4)将润湿剂加入到混合物料中制备软材;
(5)通过挤出滚圆法制备微丸;
(6)以常规的方法制备胶囊。制得的胶囊为1000粒,每粒含活性成份盐酸司来吉兰5mg;
(7)检验合格后包装得成品。
实施例2
取下列原料:盐酸司来吉兰 5g、微晶纤维素80g、羟丙纤维素10g,纯化水8g。其余同实施例1。
实施例3
取下列原料:盐酸司来吉兰 5g、微晶纤维素70g、羟丙纤维素20g,纯化水20g。其余同实施例1。
以下通过试验数据进一步说明本发明的优点 :用本发明实施例 1 的方法制备的盐酸司来吉兰胶囊剂与常规技术制备的盐酸司来吉兰胶囊剂含量均匀度与装量差异比较,结果表明本发明的制备的盐酸司来吉兰胶囊剂比常规技术制备的产品的含量均匀度与装量差异都小。
取两种样品,依法检查胶囊剂含量均匀度与装量差异(中国药典2010年版), 本发明方法制备的盐酸司来吉兰胶囊剂含量均匀度和装量差异与常规技术制备的盐酸司来吉兰胶囊剂进行对照,结果见表1。
表1 常规技术制备与本发明制备盐酸司来吉兰胶囊剂参数比较
参数 常规技术制备 本发明制备
含量均匀度(A+1.80S值) 14.1 10.6
装量差异范围 ±5.0%其中有一粒超出该范围 所测重量都在±3.0%内
从表1可以看出,两种方法制备的含量均匀度和装量差异不同,常规制备的盐酸司来吉兰胶囊剂含量均匀度和装量差异都大于本发明制备的盐酸司来吉兰胶囊剂。

Claims (2)

1.一种盐酸司来吉兰胶囊剂,其特征在于,
原料组成为:盐酸司来吉兰5份、微晶纤维素60~100份、羟丙基纤维素10~30份,纯化水5~20份;制备方法包括下列工艺步骤:
(1)称取上述微晶纤维素、羟丙基纤维素分别过60~120目筛网;
(2)将微晶纤维素与羟丙基纤维素混合均匀,得混合物料;
(3)称取上述盐酸司来吉兰和纯化水,然后将盐酸司来吉兰完全溶于纯化水中,得润湿剂;
(4)将润湿剂加入到混合物料中制备软材;
(5)通过挤出滚圆法制备微丸;
(6)以常规的方法制备胶囊;
其中挤出滚圆法采用孔径为500~1300μm的筛网;挤出滚圆法中滚圆机的转速为400~900rpm,挤出滚圆法中滚圆时间为25~300秒。
2.根据权利要求1所述的胶囊剂的制备方法,其特征在于包括下列工艺步骤:
(1)称取上述微晶纤维素、羟丙基纤维素分别过60~120目筛网;
(2)将微晶纤维素与羟丙基纤维素混合均匀,得混合物料;
(3)称取上述盐酸司来吉兰和纯化水,然后将盐酸司来吉兰完全溶于纯化水中,得润湿剂;
(4)将润湿剂加入到混合物料中制备软材;
(5)通过挤出滚圆法制备微丸;
(6)以常规的方法制备胶囊;
其中挤出滚圆法采用孔径为500~1300μm的筛网;挤出滚圆法中滚圆机的转速为400~900rpm,挤出滚圆法中滚圆时间为25~300秒。
CN201310065036.3A 2013-03-01 2013-03-01 一种盐酸司来吉兰制剂及其制备工艺 Active CN104013595B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310065036.3A CN104013595B (zh) 2013-03-01 2013-03-01 一种盐酸司来吉兰制剂及其制备工艺

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310065036.3A CN104013595B (zh) 2013-03-01 2013-03-01 一种盐酸司来吉兰制剂及其制备工艺

Publications (2)

Publication Number Publication Date
CN104013595A CN104013595A (zh) 2014-09-03
CN104013595B true CN104013595B (zh) 2016-08-24

Family

ID=51430782

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310065036.3A Active CN104013595B (zh) 2013-03-01 2013-03-01 一种盐酸司来吉兰制剂及其制备工艺

Country Status (1)

Country Link
CN (1) CN104013595B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104622826B (zh) * 2015-03-02 2018-08-10 上海普康药业有限公司 一种枸橼酸莫沙必利片剂及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2280604A (en) * 1993-07-02 1995-02-08 Resource Medical Limited Tablet formulation of betahistine and selegiline
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
GB2280604A (en) * 1993-07-02 1995-02-08 Resource Medical Limited Tablet formulation of betahistine and selegiline

Also Published As

Publication number Publication date
CN104013595A (zh) 2014-09-03

Similar Documents

Publication Publication Date Title
CN104736144B (zh) 外排抑制剂组合物和使用此组合物治疗的方法
CN104703584A (zh) 可吸入药物组合物
US11007201B2 (en) Corticotropin releasing factor receptor antagonists
JP7285222B2 (ja) 副腎皮質刺激ホルモン放出因子受容体拮抗薬
JP2012517987A5 (ja) 吸入用の医薬組成物のfpd特性を設定する方法
JP2014534196A5 (zh)
TW200820992A (en) Nanoparticulate formulations of modafinil
EP0146363B1 (en) Synergistic pharmaceutical compositions, their production and use
TW201726113A (zh) 易服用性固態製劑用粒子組成物及含有該粒子組成物之易服用性固態製劑
CN104013595B (zh) 一种盐酸司来吉兰制剂及其制备工艺
CN104510717B (zh) 奥氮平口崩片及其制备方法
HUE031442T2 (en) Use of Clidinium to improve sleep quality in respiratory patients
Huang et al. Metoprolol tartrate sustained-release binary matrix microspheres for oral administration produced by novel ultra-fine particle processing system
CN104622854A (zh) 含有盐酸氨溴索和硫酸沙丁胺醇的片剂
CN103251567A (zh) 一种阿戈美拉汀片剂及其制备方法
CN106214646B (zh) 一种水飞蓟宾葡甲胺制剂
CN105395512B (zh) 一种盐酸环苯扎林控释片
JP6055076B2 (ja) シネフリン及びトピラマートを含む組み合わせ製品
WO2016051424A4 (en) A formulation useful for delivery of neuro protecting agent
CN106692116A (zh) 一种含异佛司可林的胶囊型吸入粉雾剂
CN105641706A (zh) 一种米拉贝隆药物组合物及其制备方法
CN105796498A (zh) 一种粉末包衣叶酸及其制备方法
CN104887635B (zh) 一种盐酸西替利嗪片及其制备工艺
CN109419780A (zh) 一种盐酸索他洛尔片剂及其制备方法
JP2006528628A (ja) ヒーブ(ウマの呼吸器障害、heaves)の治療

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Hydrochloric acid selegiline preparation and preparation process thereof

Effective date of registration: 20190328

Granted publication date: 20160824

Pledgee: Hefei high tech Company limited by guarantee

Pledgor: Anhui Biochem Bio-Pharmaceutical Co., Ltd.

Registration number: 2019340000162

PC01 Cancellation of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Date of cancellation: 20200722

Granted publication date: 20160824

Pledgee: Hefei high tech Company limited by guarantee

Pledgor: Anhui Biochem Bio-Pharmaceutical Co.,Ltd.

Registration number: 2019340000162

PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: A preparation of selegiline hydrochloride and its preparation technology

Effective date of registration: 20201222

Granted publication date: 20160824

Pledgee: China Construction Bank Taihe sub branch

Pledgor: Anhui Biochem Bio-Pharmaceutical Co.,Ltd.

Registration number: Y2020340000064

PC01 Cancellation of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Date of cancellation: 20211227

Granted publication date: 20160824

Pledgee: China Construction Bank Taihe sub branch

Pledgor: Anhui Biochem Bio-Pharmaceutical Co.,Ltd.

Registration number: Y2020340000064

PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Selegilan hydrochloride preparation and its preparation process

Effective date of registration: 20211230

Granted publication date: 20160824

Pledgee: China Construction Bank Taihe sub branch

Pledgor: Anhui Biochem Bio-Pharmaceutical Co.,Ltd.

Registration number: Y2021340000043